-
EP1624871
European procedure
Extract from the Register of European Patents
EP About this file: EP1624871
| EP1624871 - METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 21.05.2010 Database last updated on 22.05.2024 | Most recent event Tooltip | 21.05.2010 | No opposition filed within time limit | published on 23.06.2010 [2010/25] | Applicant(s) | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065 / US | For all designated states Merck Frosst Canada Ltd. 16711 Trans-Canada Highway Kirkland, Québec H9H 3L1 / CA | [2010/10] |
| Former [2006/07] | For all designated states Merck & Co., Inc. (a New Jersey corp.) 126 East Lincoln Avenue Rahway, N.J. 07065 / US | ||
| For all designated states Merck Frosst Canada Ltd. 16711 Trans-Canada Highway Kirkland, Québec H9H 3L1 / CA | Inventor(s) | 01 /
CHENG, Kang 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | 02 /
WATERS, M., Gerard 126 East Lincoln Avenue Rahway, NJ 07065-0907 / US | 03 /
METTERS, Kathleen, M. 16711 Trans-Canada Highway Kirkland, Québec H9H 3L1 / CA | 04 /
O'NEILL, Gary 16711 Trans-Canada Highway Kirkland, Québec H9H 3L1 / CA | [2006/07] | Representative(s) | Horgan, James Michael Frederic, et al Merck Sharp & Dohme Corp. 120 Moorgate London, EC2M 6UR / GB | [N/P] |
| Former [2006/48] | Horgan, James Michael Frederic, et al Merck & Co., Inc. European Patent Department Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon Hertfordshire, EN11 9BU / GB | ||
| Former [2006/07] | Horgan, James Michael Frederic Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road Harlow, Essex CM20 2QR / GB | Application number, filing date | 04785539.0 | 13.05.2004 | [2006/07] | WO2004US14980 | Priority number, date | US20030470665P | 15.05.2003 Original published format: US 470665 P | [2006/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2004103370 | Date: | 02.12.2004 | Language: | EN | [2004/49] | Type: | A1 Application with search report | No.: | EP1624871 | Date: | 15.02.2006 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.12.2004 takes the place of the publication of the European patent application. | [2006/07] | Type: | B1 Patent specification | No.: | EP1624871 | Date: | 15.07.2009 | Language: | EN | [2009/29] | Search report(s) | International search report - published on: | EP | 02.12.2004 | Classification | IPC: | A61K31/455, A61K31/00, A61K31/403, A61K31/437, A61K31/538, A61P3/06 | [2006/07] | CPC: |
A61K31/4745 (EP,US);
A61K31/455 (EP,KR,US);
A61K31/403 (EP,KR,US);
A61K31/437 (EP,US);
A61K31/538 (EP,US);
A61K31/69 (EP,US);
A61P3/00 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
| C-Set: |
A61K31/403, A61K2300/00 (EP,US);
A61K31/437, A61K2300/00 (US,EP);
A61K31/455, A61K2300/00 (US,EP);
A61K31/4745, A61K2300/00 (US,EP); | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR [2006/07] | Extension states | AL | 15.12.2005 | HR | 15.12.2005 | LT | 15.12.2005 | LV | 15.12.2005 | MK | 15.12.2005 | Title | German: | VERFAHREN ZUR BEHANDLUNG VON ATHEROSKLEROSE, DYSLIPIDÄMIE UND VERWANDTEN ERKRANKUNGEN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN | [2006/07] | English: | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | [2006/07] | French: | METHODE DE TRAITEMENT DE L'ATHEROSCLEROSE, DYSLIPIDEMIE ET ETATS RELATIFS ET COMPOSITIONS PHARMACEUTIQUES | [2006/07] | Entry into regional phase | 15.12.2005 | National basic fee paid | 15.12.2005 | Designation fee(s) paid | 15.12.2005 | Examination fee paid | Examination procedure | 15.12.2005 | Examination requested [2006/07] | 22.01.2008 | Despatch of a communication from the examining division (Time limit: M04) | 23.05.2008 | Reply to a communication from the examining division | 05.06.2008 | Despatch of a communication from the examining division (Time limit: M04) | 09.10.2008 | Reply to a communication from the examining division | 21.01.2009 | Communication of intention to grant the patent | 21.04.2009 | Fee for grant paid | 21.04.2009 | Fee for publishing/printing paid | Divisional application(s) | EP09163448.5 / EP2116244 | EP10182413.4 / EP2286816 | Opposition(s) | 16.04.2010 | No opposition filed within time limit [2010/25] | Fees paid | Renewal fee | 27.03.2006 | Renewal fee patent year 03 | 07.05.2007 | Renewal fee patent year 04 | 18.03.2008 | Renewal fee patent year 05 | 02.06.2009 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO9632942 (VITAL THERAPEUTICS L L C [US], et al) [Y] 1-10* page 3, line 3 - line 17 *; | [XY]WO0179169 (MERCK FROSST CANADA INC [CA], et al) [X] 5-10 * page 9, line 21 - line 23 * * page 10, line 20 - line 22 * * see formula (I) * [Y] 1-10; | [XY]WO0208186 (MERCK FROSST CANADA INC [CA], et al) [X] 5-10 * page 17, line 20 - line 22 * * page 21, line 17 - line 18 * [Y] 1-10; | [XY]WO02094830 (MERCK FROSST CANADA INC [CA], et al) [X] 5-10 * page 21, line 8 - line 13 * * page 22, line 9 - line 10 * * see especially compound 122 on page 49 * [Y] 1-10 | Examination | - KANG C. ET AL, "Antagonism of the prostaglandin D-2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans", PNAS, (20060425), vol. 103, no. 17, doi:doi:10.1593/neo.05394, pages 6682 - 6687, XP008110064 DOI: http://dx.doi.org/10.1593/neo.05394 | by applicant | US4166452 | US4256108 | US4265874 | US4342767 | US4346227 | US4444784 | US5260440 | US5273995 | US5354772 | WO9508532 | WO9716424 | WO9716455 | US5631365 | WO9723200 | WO9745406 | US5739321 | US5756470 | US5767115 | US5846966 | US5856473 | US5886171 | US5919672 | WO0020623 | WO0034240 | WO0038725 | WO0060107 | US6133001 | WO0063703 | WO02084298 | - LORENZEN, A. ET AL., MOLECULAR PHARMACOLOGY, (2001), vol. 59, pages 349 - 357 | - LORENZEN, A. ET AL., BIOCHEMICAL PHARMACOLOGY, (2002), vol. 64, pages 645 - 648 | - SOGA, T. ET AL., BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMM., (2003), vol. 303, pages 364 - 369 | - TUNARU, S. ET AL., NATURE MEDICINE, (2003), vol. 9, pages 352 - 355 | - WISE, A. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (2003), vol. 278, pages 9869 - 9874 | - VAN HERK, T. ET AL., JOURNAL OF MEDICINAL CHEMISTRY, (2003), vol. 46, pages 3945 - 3951 | - ABRAMOVITZ M ET AL., BIOCHEM. BIOPHYS. ACTA, (2000), vol. 1483, pages 285 - 293 | - SAWYER N ET AL., BR. J. PHARMACOL., (2002), vol. 137, pages 1163 - 1172 |